	US 12,227,575 B2
	Combination of TIM-4 antagonist and PD-1 antagonist and methods of use
Sean E. Doyle, Seattle, WA (US); Mark J. Selby, San Francisco, CA (US); and Eric Chadwick, Bellevue, WA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Filed on Mar. 14, 2022, as Appl. No. 17/693,975.
Application 17/693,975 is a division of application No. 16/314,732, granted, now 11,306,143, previously published as PCT/US2017/040665, filed on Jul. 5, 2017.
Claims priority of provisional application 62/359,073, filed on Jul. 6, 2016.
Prior Publication US 2022/0275091 A1, Sep. 1, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 2039/507 (2013.01); C07K 2317/76 (2013.01)]

15 Claims

1. A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of:

(a) an anti-PD-L1 antibody comprising a means for binding PD-L1 and inhibiting binding of PD-L 1 to the PD-1 receptor; and

(b) an anti-TIM-4 antibody comprising a means for binding TIM-4 and inhibiting efferocytosis of tumor cells.